Since the Tyr promoter-driven gene nanomedicine NPTyr-C9AP has been proven to enhance antitumor T-cell responses by melanoma-specific coexpression of CXCL9 and αPD-L1, we explored engineering a universal gene nanomedicine that enables coexpression of CXCL9 and αPD-L1 specifically in various tumor cells for enhanced immunotherapy against multiple tumors. This evidence concerns the gene CXCL9 and neoplasm.